Business Wire

SMITHS-DETECTION

26.3.2021 08:02:07 CET | Business Wire | Press release

Share
Heathrow selects Smiths Detection for its next generation cabin baggage and security screening equipment

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has been chosen to supply integrated checkpoints throughout Heathrow Airport, featuring the HI-SCAN 6040 CTiX computed tomography X-rays, to deliver an advanced level of security and efficiency.

The ECAC EDS CB C3 approved CT systems will see Heathrow meet the highest regulatory requirements, while helping the leading airport achieve its vision for the future of the security checkpoint for passengers and colleagues. The integrated checkpoints feature iLane automatic tray return systems and Checkpoint.Evoplus , Smiths Detection’s checkpoint operation management solution. The award also includes a 10-year equipment service agreement.

“We are delighted to once again be given the opportunity to work closely with Heathrow Airport to provide leading-edge technologies that bring the best security outcomes and passenger experience,” said Smiths Detection President, Roland Carter. “Both Smiths Detection and Heathrow are focused on intelligent solutions that deliver efficiency, security and resilience; and these new lanes will allow for improvements to be easily integrated as technology develops.”

As part of its decision making, Heathrow sought a supplier that could deliver a large scale, innovative, end-to-end solution and integrate the lanes into the airports’ existing operational environment with no impact to capacity or passenger experience.

Each piece of the integrated checkpoint uses Smiths Detection’s leading-edge technology designed to help increase security, improve passenger experience, and enhance operational efficiency:

  • HI-SCAN 6040 CTiX – This CT technology cabin baggage screening system provides the highest level of detection using 3D images with low false alarm rates. It delivers advanced explosives detection and can allow for electronics and liquids to remain in bags, helping to expedite the screening process.
  • Checkpoint.Evoplus fully integrates the checkpoint by combining individual components of the lane onto a single, intelligent operational management solution. It enables centralised screening by delivering scanned images to operators based at separate locations, resulting in optimised resources management and reduced operational costs.
  • iLane - a family of automatic tray return systems that use a modular smart lane design. By delivering a steady flow of trays, iLanes help remove bottlenecks and streamline the screening process to deliver higher throughput. The family includes iLane Selfcair, iLane.evo, and iLane.pro.

This contract is part of a long-term relationship between Heathrow and Smiths Detection, which includes the supply of industry leading hold baggage CT solutions.

The first lanes will be installed in anticipation of a recovery in passenger numbers later this year.

###

About Smiths Detection

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – we do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information on Smiths Detection’s solutions and services, visit https://www.smithsdetection.com/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye